For over five decades, Mumbai, Maharashtra-based Bharat Serums & Vaccines Ltd (BSV) has used its scientific resources to develop a range of biological, biotech, and pharmaceutical products focused on women’s health and infertility treatments.
Tarun Bhardwaj of the Financial Express interviewed Sanjiv Navangul, managing director & CEO, of BSV to discuss the company’s efforts on augmenting and strengthening their portfolio related to women’s health.
Excerpts from the Interview:
On what makes BSV a women-centric biopharma company
Navangul: We work towards addressing the unmet medical needs of reproductive health for women. including products for preventing Rh isoimmunization, endometriosis, postpartum hemorrhage, luteal deficiency, and a wide category of gonadotropins.
On the company’s global operations
Navangul: We have three wholly owned subsidiaries in the Philippines, Germany and the U.S. Our team in Germany manufactures therapeutic proteins derived from natural sources. Our U.S.-based research and drug development organization is dedicated to early-stage development of recombinant molecules. We have built business efficiencies for our partner companies across the globe. Our 300+ member-teams across the globe have made a measurable impact on health and quality of life globally.
